Tri Locum Partners LP Decreases Stake in United Therapeutics Corporation $UTHR

Tri Locum Partners LP decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 41.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,370 shares of the biotechnology company’s stock after selling 50,551 shares during the period. United Therapeutics accounts for about 5.9% of Tri Locum Partners LP’s portfolio, making the stock its 9th biggest holding. Tri Locum Partners LP’s holdings in United Therapeutics were worth $41,728,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Torren Management LLC purchased a new stake in United Therapeutics during the 4th quarter valued at approximately $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the 4th quarter worth $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.2%

United Therapeutics stock opened at $524.70 on Thursday. The firm has a market cap of $22.27 billion, a P/E ratio of 19.37, a P/E/G ratio of 1.75 and a beta of 0.58. The business has a fifty day moving average of $545.45 and a two-hundred day moving average of $532.24. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $6.63 EPS. Equities analysts expect that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 502,833 shares of company stock valued at $279,835,157 over the last quarter. 8.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the subject of a number of research reports. Royal Bank Of Canada increased their target price on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.